Uphine versus diphenhydramine for the prevention of epidural morphine-induced pruritus afterUphine versus diphenhydramine for the

Uphine versus diphenhydramine for the prevention of epidural morphine-induced pruritus after
Uphine versus diphenhydramine for the prevention of epidural morphine-induced pruritus soon after cesarean delivery. Chang Gung Med J. 2011;34(two):172. 21. Wang JJ, Ho ST, Hu OY. Comparison of intravenous nalbuphine infusion versus saline as an adjuvant for epidural morphine. Reg Anesth. 1996;21(three):214. 22. Wang JJ, Ho ST, Tzeng JI. Comparison of intravenous nalbuphine infusion versus naloxone inside the prevention of epidural morphine-related unwanted effects. Reg Anesth Pain Med. 1998;23(five):4794. 23. Wittels B, Glosten B, Faure EA, Moawad AH, Ismail M, Hibbard J, et al. Opioid antagonist adjuncts to epidural morphine for postcesarean analgesia: maternal outcomes. Anesth Analg. 1993;77(5):9252. 24. Hawi A, Hunter R, Morford L, Sciascia T. Nalbuphine attenuates itch in the Substance-P induced mouse model. Acta Derm Venereol. 2013;93:S634.25. Johnson SJ. Opioid safety in patients with renal or hepatic dysfunction. In: Discomfort Remedy Topics. 2007. paincommunity.org/blog/wp-content/ uploads/Opioids-Renal-Hepatic-Dysfunction.pdf. 26. Mercadante S, Arcuri E. Opioids and renal function. J Pain. 2004;5(1):29. 27. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):6134. 28. Aitkenhead AR, Lin ES, Achola KJ. The pharmacokinetics of oral and intravenous nalbuphine in healthful volunteers. Br J Clin Pharmacol. 1988;25(two):264. 29. Jaillon P, Gardin ME, Lecocq B, Richard MO, Meignan S, Blondel Y, et al. Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. Clin Pharmacol Ther. 1989;46(two):2263. 30. Errick JK, Heel RC. Nalbuphine. A preliminary review of its pharmacological properties and therapeutic Adenosine A2B receptor (A2BR) Antagonist MedChemExpress efficacy. Drugs. 1983;26(3):19111. 31. Schmidt WK, Tam SW, Shotzberger GS, Smith Jr DH, Clark R, Vernier VG. Nalbuphine. Drug Alcohol Depend. 1985;14(3):3392.Submit your subsequent manuscript to BioMed Central and take full advantage of:Convenient online submission Thorough peer assessment No space constraints or colour figure charges Quick publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Study that is freely offered for redistributionSubmit your manuscript at biomedcentral.com/submit
Lu et al. Molecular NeuroTLR9 list degeneration 2014, 9:17 molecularneurodegeneration.com/content/9/1/RESEARCH ARTICLEOpen AccessThe Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axonsXi Lu1, Jeong Sook Kim-Han2, Steve Harmon2, Shelly E Sakiyama-Elbert1* and Karen L O’MalleyAbstract6-hydroxydopamine (6-OHDA) is amongst the most commonly used toxins for modeling degeneration of dopaminergic (DA) neurons in Parkinson’s illness. 6-OHDA also causes axonal degeneration, a procedure that seems to precede the death of DA neurons. To know the processes involved in 6-OHDA-mediated axonal degeneration, a microdevice designed to isolate axons fluidically from cell bodies was made use of in conjunction with green fluorescent protein (GFP)-labeled DA neurons. Benefits showed that 6-OHDA rapidly induced mitochondrial transport dysfunction in each DA and non-DA axons. This appeared to become a general effect on transport function due to the fact 6-OHDA also disrupted transport of synaptophysin-tagged vesicles. The effects of 6-OHDA on mitochondrial transport were blocked by the addition on the SOD1-mimetic, Mn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP), too as the anti-oxidant N-acetyl-cysteine (NAC) suggesting that totally free radical species played a function in this method. Temporally, microtubule disruption and autophagy occurre.